DATA presented at AAIC 2026 has shown that a blood test measuring the Alzheimer’s biomarker p-tau217 could predict a person’s risk of cognitive decline up to a decade before symptoms appear, potentially transforming early detection and prevention efforts.
Alzheimer’s Blood Test Offers a New Prognostic Tool
Plasma p-tau217 is already known to closely track amyloid and tau pathology associated with Alzheimer’s disease on PET imaging, but its value for predicting long-term outcomes in cognitively unimpaired adults has remained unclear. Researchers therefore pooled data across several longitudinal cohorts to establish prognostic estimates for clinical progression from a simple blood test.
Data from Nearly 2,700 Cognitively Healthy Adults
Researchers analysed harmonised data from 2,705 cognitively unimpaired participants, with a mean age of 70 years, drawn from five cohorts: A4/LEARN, HABS, ADNI, WRAP and HABS-HD. Participants were selected based on their first plasma p-tau217 measurement and at least one year of follow-up, averaging 4.7 years and extending beyond a decade in some cases. Cox proportional-hazards models examined the relationship between p-tau217 and time to mild cognitive impairment, dementia, or sustained clinical dementia rating of 0.5 or higher, adjusting for age, sex, APOE ε4 status and education, with additional models incorporating amyloid PET data.
Very High p-Tau217 Levels Linked to Steep Rise in Risk
Higher p-tau217 predicted faster cognitive decline (β=−0.14; p<0.001), with the strongest effects seen in participants with elevated amyloid burden (β=−0.06; p<0.001). Each one standard deviation increase in p-tau217 was associated with a 38% increased hazard of progression to clinical impairment (95% CI 31 to 44%; p<0.0001), independent of age, sex, APOE ε4 status and education. Risk was highest in the very high p-tau217 category, corresponding to an estimated 78% likelihood of cognitive impairment over 10 years and roughly a 1-in-3 chance within five years, while those with moderately elevated levels had an estimated 15% risk over five years and 45% over 10 years. Blood test results added predictive information beyond that provided by brain imaging and genetic testing.
A Step Toward Predictive, Personalised Alzheimer’s Care
The authors concluded that plasma p-tau217 shows robust prognostic value over five and ten years in cognitively unimpaired older adults, positioning this blood test as a tool for identifying at-risk individuals for Alzheimer’s prevention trials and for guiding future treatment and monitoring decisions.
Reference
Buckley RF et al. The prognostic value of p-tau217 levels on progression to clinical impairment over 2, 5, and 10 years. Presentation. AAIC, 12-15 July, 2026.
Featured image: Pixel-Shot on Adobe Stock
- Author:
